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Abstract
Background. Although gastrointestinal (GI) symptoms
are very frequent in organ transplant patients, there is a
paucity of data about the endoscopic findings of kidney
recipients.
Methods. Two thousand one hundred and thirty-five kid-
ney transplants were performed between 1994 and 2007.
During that period, 672 gastroscopies were performed in
543 of those patients. Their mean age was 49.5 years and
56.9% were male. Immunosuppressive combinations in-
cluded cyclosporine–mycophenolate–steroids, cyclosporine–
steroids and tacrolimus–mycophenolate mofetil–steroids.
Ninety-eight percent of the patients received acid suppres-
sion therapy.
Results. The rate of clinically significant endoscopic find-
ings was 84%. Macroscopic findings included inflamma-
tion in 46.7%, oesophagitis in 24.7%, ulcer in 16.9%
and erosions in 14.8% of cases. Twenty-nine percent of en-
doscopies showed ulcer disease more frequently in the first
3 months (P = 0.0014) after transplantation than later, and
45.7% of all ulcers developed in the first year. The pres-
ence of Helicobacter pylori was verified in 20.9% of
cases, less than in the general, and also in the uraemic
population (P < 0.0001). There was no association between
the presence ofH. pylori and ulcers (P = 0.28). Steroid pulse
treatment for rejection was not associated with more ulcers
(P = 0.11); the use of mycophenolate mofetil increased the
risk of erosions by 1.8-fold.
Conclusion. More than 25% of all kidney recipients re-
quired upper endoscopy in their ‘post-transplant life’; the
prevalence of ‘positive findings’ and ulcer disease was
higher than in the general population (P < 0.0001). The
most vulnerable period is the first 3 months. Mycopheno-
late mofetil had an impact on GI complications, whilst the
presence of H. pylori in the transplant population is not
associated with the presence of ulcers.
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Introduction
Upper gastrointestinal (GI) symptoms are frequent in organ
transplant recipients. Peptic ulcers and related pathologies
such as gastritis and duodenitis are known to occur with in-
creased frequency (20–60%) and severity in renal transplant
recipients. The frequency of severe complications is about
10% among transplant recipients and 10% of those might
prove fatal [1–5]. Compared to the general population,
renal transplant recipients have an age-adjusted ratio for
GI bleeding of 10.69 at 1 year of follow-up [6]. Frequency of
ulcer disease was proven to be 8.3–10.7% of endoscopically
examined general gastroenterology patients [7,8]. Similar
data among transplant patients are not available. GI compli-
cations might play a role in the outcome of kidney trans-
plantation, as they are associated with an increased risk
of graft loss, since dose reduction or even withdrawal
of immunosuppressive (IS) agents might be necessary
[3, 9–11]. Different factors can cause GI symptoms: surgi-
cal stress, the operation itself, local irritant and pro-inflam-
matory effects of IS and/or other drugs, the numerous pills
some patients have to take every day and bacterial, viral and
mycotic infections [12,13]. The GI tract accounts for a large
component of non-allograft-related complications seen after
all types of solid organ transplantation [14]. Whilst endo-
scopic alterations of liver transplant recipients are the focus
of numerous studies [15–18], only few studies have been
done on the endoscopic findings of renal patients and in-
clude only small numbers [19,20].
By summarizing and analysing the largest endoscopic
database in the literature, our aim was to ascertain the fre-




From January 1994 to December 2007, 2143 kidney transplants were per-
formed in a large transplant centre. Six hundred and seventy-two upper GI
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endoscopies were done in 543 kidney transplant patients (25.3% of reci-
pients). Patients with GI complaints following informed written consent,
underwent an upper endoscopy examination; 56.9% of them were male,
with a mean age of 49.5 ± 12.8. All patients received an acid-blocker as
ulcer prophylaxis. Data of kidney transplant patients were collected for
this cross-sectional (date of endoscopy), descriptive study.
Endoscopy
Two senior surgeon-gastroenterologists performed all the endoscopic ex-
aminations esophago-gastro-duodenoscopy = gastroscopy (EGD). The
upper GI tract was examined. The endoscopic abnormalities were evalu-
ated according to international standards [21–25]. Forceps mucosal biop-
sies were taken from a specific lesion (e.g. ulcer) if present and from
every patient from the first part of the duodenum, the gastric antrum
and the gastric corpus (2-2 biopsy samples from each localization). Bi-
opsy samples were investigated by conventional histology for mucosal
changes (haematoxylin–eosin and Giemsa). Patients were considered as
Helicobacter pylori (H. pylori) positive, if histology proved its presence.
No biopsy was taken in cases of bleeding, in patients with known coagu-
lation disorders or those on anticoagulant therapy (except aspirin).
Immunosuppression and acid suppressive therapy
The IS medication used at the time of endoscopy was collected and ana-
lysed. Cyclosporine (CSA), tacrolimus (TAC), mycophenolate mofetil
(MMF) and steroids (ST) were used in various combinations for mainten-
ance therapy. ST were administered in a tapering dose once a day. CSA,
TAC and MMF were administered twice daily. Target trough levels of
CSA were 150–200 ng/mL and TAC were 7–10 ng/mL at the long term.
The initial dose of MMF was 2 × 1 g, according to an established protocol.
Prednisolone or methylprednisolone was used as ST. At the time of EGD,
the most frequently used (75.1%) IS combinations were CSA–MMF–ST
triple treatment, CSA–ST double treatment and TAC–MMF–ST triple
therapy. All other combinations occurred in <5% in that material, and
these were excluded from the IS-related analysis. A total of 34.51% of
all transplant recipients and 34.56% of endoscopically examined patients
received intravenous ST pulse therapy. Out of the latter ones, 15.53%
received it in the 3 months period prior to the endoscopy.
Data of acid suppressive therapy (AST) ‘before’ endoscopy were also
collected and analysed. Nearly all (97.8%) patients received AST. Out of
them, 56.1% received a histamine receptor antagonist (H2RA) and 43.8%
a proton pump inhibitor (PPI). There was a variable usage of PPIs and H2
receptor antagonists; however, the general use did not change during the
study period. There was no difference between the IS groups according to
AST treatment received, P = 0.33.
Statistical analysis
Qualitative data were analysed by Fisher’s exact test or with chi-square
test with a two-sided probability value. Continuous variables were com-
pared using the Mann–Whitney U or Kruskal–Wallis test. Frequencies of
specific pathologic phenomena were calculated by direct counting. The
influence of risk factors was quantified using odds ratio (OR). P-values
of below 0.05 were considered significant. Statistics were performed




Only 16.2% of the patients examined had the absence of
any abnormal endoscopic findings. The most frequent ab-
normality found were inflammatory changes, with almost
one-half of the patients showing signs of gastritis and/or
duodenitis. Oesophagitis, varices, duodenal and/or gastric
ulcer disease, erosions, oesophageal varices and polypoid
lesions were frequently observed findings. Their frequency
was independent from renal function assessed by serum-
creatinine level (Table 1). Fifty-two out of 92 ulcer patients
(56.5%) had gastric, 33 (35.8%) duodenal and 7 (7.6%)
both kinds of ulcer. In five cases, malignant tumour was
suspected during the endoscopy with three of them histologi-
cally proven: one of those was mucosa associated lymphoid
tissue (MALT) lymphoma, the otherswere adenocarcinomas.
Altogether six malignant tumours were found, in the other
three cases, previously a diagnosis of polyp or ulcer was
made. Other rare abnormalities seen were diverticula, vas-
cular angiectasia (suspicious for Kaposi-sarcoma) and
Mallory–Weiss syndrome.
H. pylori
In 62 (11.4%) cases, the H. pylori status was not deter-
mined. These examinations were mainly repeated or acute
endoscopies for bleeding. Out of the 481 histologically
examined, the presence of H. pylori was verified in 101
cases, representing 20.9%. For a two-year period during
the study we performed histology and rapid urease test
(RUT) in parallel. Whilst the specificity of RUT was
98.5%, its sensitivity was only 38.5%, so we stopped per-
forming it in 2004. There was no difference according to
gender or age (Table 2).
The presence of H. pylori was not associated with the
presence of peptic ulcer: 20 of 101 H. pylori-positive pa-
tients as compared to 57 of 380 H. pylori-negative patients
had ulcers (P = 0.28). Vice versa: 26% of ulcer patients
were positive forH. pylori. Therewere no significant associa-
tions between positivity for H. pylori and erosions, oeso-




Serum creatinine, if the lesion is
PPresent Not present
Inflammation 46.7% 22.2% 0.57 147 130 0.45
Oesophagitis 24.9% 19.8% 0.80 128 141 0.95
Ulcer 16.9% 26% 0.28 120 140 0.19
Erosions 14.8% 16.7% 0.41 150 130 0.24
Varices 3.8% 20.8% 0.58 176 130 0.22
Polypoid lesions 2.9% 20.9% 0.75 150 130 0.81
Negative 16.2% 21.9% 0.36 130 140 0.20
H. pylori 20.9% 130 140 0.85













phagitis, macroscopic signs of inflammation, metaplasia or
atrophy (Table 1).
Impact of IS agents
We compared the main groups according to the observed
diagnosis and infection rate. There were no differences in
the incidence of negative findings, inflammation, ulcer
and oesophagitis and the presence of H. pylori. However,
there were differences in the incidence of erosive lesions;
both the differences between the groups and the trend
(P = 0.01) are significant (Table 3). This table displays the
rate of the particular lesions of those receiving ST pulse
every three months prior to endoscopy as well. Out of them,
18.75% had an ulcer (P = 0.106). MMF was proven as an
independent risk factor for erosive lesions, OR: 1.83 (1.02–
3.29, P = 0.043) when correcting for the presence of other
risk factors.
Impact of acid suppression therapy
We compared the H2RA and PPI groups according to the
indications, observed diagnoses and infections. These
groups did not differ in their nature of presenting com-
plaints: pain, dyspepsia, anaemia and bleeding occurred
at the same rate. Respective P-values were 0.9, 0.55, 0.16
and 0.86. There was no difference in the incidence of in-
flammation (P = 1.0), oesophagitis (P = 0.68), erosions
(P = 0.60), ulcers (P = 0.20) or negative findings (P =
0.87) depending on the AST given, and there was no differ-
ence in mycosis (P = 0.16). The only significant difference
was in the presence of H. pylori; it was present in 22.6%
of patients who received H2RA and in 12.4% of those
who received PPI (P = 0.044).
Timing of endoscopy
The time between transplantation and endoscopy varies
from 3 days up to almost 19 years, median was 3.39 years.
However, 29% (157) of the patients were examined in the
first post-transplant year, and 58.5% (92) of them, which is
16.9% of all, in the first 3 months, as shown in Figure 1.
Ulcers were more commonly found in patients requiring
earlier endoscopy: 1.65 vs 3.66 years for patients where no
ulcer was found (P = 0.009). The frequency of ulcer disease
was 29.3% of the examinations in the first 3 months, 26.3%
in the first year and only 12.9% later on, P = 0.0014.
Twenty-seven (29.3%) out of 92 ulcers developed in the
first 3 months, forty-two (45.7%) in the first year and all
the others at a constant rate later on (Figure 2). The H. pyl-
ori positivity rate on examination decreased with time after
transplantation, but this was statistically non-significant.
Discussion
This is the largest series, to our knowledge, of endoscopic
findings in consecutive kidney transplant patients scoped
for a specific indication. Endoscopy is not part of the rou-
tine pre- or postoperative schedule in this unit. By nature,
this examination is relatively unpleasant, invasive and ex-
pensive, with a small but existing hazard of perforation of
about 0.06% [26].
We included only endoscopies performed in our centre
on those patients to guarantee homogeneity. The way of
follow-up in our centre, though, means that only few en-
doscopies (perhaps <5%) were performed elsewhere. Ac-
cording to our study, at least 25% of all patients require
upper endoscopy in their ‘post-transplant life’. We did
not find data to compare this rate.
Endoscopy was completely negative in about 16% of
our cases, which reflects other reports [20]. This rate
(84%) of clinically significant endoscopic findings is
much higher than expected from data of general gastro-
enterology patients, where this figure is around 58%
[7,27].
The most important period for upper GI symptoms re-
quiring endoscopy was the first year and particularly the
first 3 months. Almost one-third of the patients were inves-
tigated in the first year. The importance of the first year
was observed in other reports as well, where 51% of the
verified GI complications occurred during that time [5].
In the first 3 months 29%, and in the first year 26% of
the endoscopic examinations revealed an ulcer disease.
Out of 92 ulcers, 29% developed in the first 3 months
and 45.7% in the first post-transplant year. The nearly
17% incidence of well-defined ulcer disease is signifi-
cantly (P < 0.0001) higher comparing it with gastroenter-
ology patients undergoing endoscopy [7,8]. The risk of
ulcer disease is 1.69-fold (1.32–2.15 confidence interval
(CI) 95%) for a kidney recipient. There are no similar
data for the prevalence of ulcers in transplant patients
in the literature. The true prevalence of ulcer disease
might be even higher, as a large proportion of patients
do not experience symptoms [28].
Table 2. Demographic data according H. pylori
H. pylori pos. H. pylori neg. P
Male (56.55%) 20.96% 79.04% P = 1.0
Female (43.45%) 21.05% 78.95%
Age (year) 50.54 49.24 0.53
Table 3. GI lesions and their frequency according to the IS regimen and steroid pulse therapy
CSA–ST CSA–MMF–ST TAC–MMF–ST P ST pulse P
Negative 12.0% 13.9% 17.9% 0.53 25.0% 1.00
Inflammation 51.0% 50.5% 38.5% 0.15 31.23% 0.18
Ulcer 19.0% 16.1% 15.4% 0.77 18.8% 0.11
H. pylori 24.7% 23.9% 17.3% 0.45 7.1% 0.18
Erosions 15.9% 18.4% 24.4% 0.03 31.2% 0.0547













The individual IS drugs and combinations received
seemed to have a significant impact on the patient’s GI
status. MMF was proven to increase the risk of erosions
of the gastro-duodenal mucosa 1.83-fold (1.02–3.29 CI
95%). Patients receiving the TAC–MMF–ST regimen
had the highest frequency of erosive lesions. The effect
of corticosteroids is still controversial; high doses are sus-
pected to be ulcerogenic, but real evidence is not available
[12,29–31]. ST treatment can mask the symptoms and
delay treatment [32]. In our series, even high-dose intra-
venous ST pulse therapy for rejection was not associated
with GI lesions observed endoscopically.
Administration of AST for ulcer prophylaxis is com-
mon at most transplant centres [1,12,33,34]. The specific
drug used in our centre was dependent on availability,
price etc. and not only on medical grounds. The rate of
observed endoscopic alterations did not differ in the
H2RA and in the PPI group, indicating the equivalence
of these two groups of AST in this setting. The only dif-
ference was in the presence of H. pylori; PPIs facilitated
the eradication ‘by chance’ more efficiently than they do
in the general population.
Over the last 20 years there has been considerable inte-
rest in the role of H. pylori in the pathogenesis of gastritis
and peptic ulceration in the general population [35]. Data
reported on the prevalence of Helicobacter pylori among
transplant recipients are contradictory. There are only a
few studies reporting endoscopic results of transplant pa-
No and rate of endoscopies in the posttransplant years
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Fig. 1. No. of endoscopies in the post-transplant years.
Fig. 2. Rate of observed ulcers according to post-transplant years.













tients [2,36–38], and there are some more reporting of H.
pylori serologic examinations [39–41]. Published data vary
from 29 to 70%. Seroprevalence of H. pylori is 49% in a
large Hungarian uraemic cohort [42]. In our endoscopic
unit experience, 47% H. pylori positivity rate was detected
with biopsy in general gastroenterology patients during the
same period (data not published). The observed 20.9% fre-
quency of biopsy-proven H. pylori infections in our study
represented a highly significant difference (P < 0.0001).
Our results demonstrated a high, ‘spontaneous’ eradication
rate in transplanted patients. The rate of H. pylori did not
change in time in our present material, and the age of posi-
tivity and negativity was the same. These results suggest
that eradication happens at the very early peri-operative
period, when prophylactic antibiotics and AST are given
together. The presence of H. pylori did not result in signifi-
cant postoperative gastric complications. Due to the con-
stant use of AST, the sensitivity of RUT was only 38.5%.
As a result, we do not recommend it in this particular group
of patients. As both Helicobacter pylori [43] and immuno-
suppression have been linked to an increased risk of devel-
oping malignancy, we considered our patients as ‘high-risk
patients’, and a ‘test and treat’ strategy was followed. The
Maastricht Consensus Reports were used as basis for the
eradication protocol [44].
In the general population, only 15% of H. pylori-infected
persons develop peptic ulcer disease, suggesting that spe-
cific factors are required for ulceration to occur [45]. Less
than one-third (26%) of gastric ulcer patients wereH. pylori
positive and even less (17%) were positive among patients
found to have a duodenal ulcer. Neither the type of IS drugs
nor the presence of H. pylori had a statistically significant
impact on ulceration. This finding suggests that ulceration
in transplant recipients is a multifactorial process that may
involve the interaction of acid secretion, H. pylori, IS
agents and other medications rather than a single factor.
Specific IS drugs, opportunistic infections and other
clinical circumstances that affect transplant patients are
not seen frequently in the general practice of gastroenter-
ology. Thus, the endoscopist at a transplant centre has to
be able to recognize, identify and treat the unique pro-
blems seen in a transplant population. Giving prophylac-
tic acid secretion blockers, minimizing the number of pills
a patient has to take a day and adopting a low threshold
for endoscopy are among the most important measures
that could be used to avoid GI complications after trans-
plantation [46].
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Abstract
Background. Among eligible transplant candidates with
end-stage renal disease, only a minority receive a living
donor kidney transplant (LDKT), suggesting that there
are barriers to receipt of this optimal therapy.
Methods. A validated questionnaire was administered to
adults active on the deceased donor transplant waiting list,
identified from the Southern Alberta Renal Program data-
base. The questionnaire included both quantitative and
qualitative items addressing issues related to LDKT in
the categories of knowledge, opportunity, fear and guilt.
Results. Of the 196 subjects invited to complete the ques-
tionnaire, 145 (74%) responded. Not knowing how to ask
someone for their kidney was the most frequently reported
barrier, identified by 71% of respondents. Those that sta-
ted that living donation did not pose significant long-term
health risks to the donor [odds ratio (OR) = 3.40, 95% CI
1.17–9.46, P = 0.01] and those who understood how and
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